1.1 Nivolumab is recommended for use within the Cancer Drugs Fund as an option for treating locally advanced or metastatic non-squamous non-small-cell lung cancer in adults after chemotherapy, only if:
their tumours are PD‑L1 positive and
nivolumab is stopped at 2 years of uninterrupted treatment, or earlier in the event of disease progression, and
the conditions in the managed access agreement are followed.
1.2 This recommendation is not intended to affect treatment with nivolumab that was started in the NHS before this guidance was published. People having treatment outside this recommendation may continue without change to the funding arrangements in place for them before this guidance was published, until they and their NHS clinician consider it appropriate to stop.